Compare CABO & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABO | STTK |
|---|---|---|
| Founded | 1980 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 540.0M | 569.1M |
| IPO Year | 2015 | 2020 |
| Metric | CABO | STTK |
|---|---|---|
| Price | $75.88 | $7.03 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $125.67 | $10.00 |
| AVG Volume (30 Days) | 95.3K | ★ 424.3K |
| Earning Date | 04-30-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ 6.12 | N/A |
| Revenue | ★ $1,501,423,000.00 | $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.83 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $70.37 | $0.71 |
| 52 Week High | $187.90 | $8.33 |
| Indicator | CABO | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 30.95 | 49.99 |
| Support Level | $70.37 | $5.75 |
| Resistance Level | $117.15 | $7.68 |
| Average True Range (ATR) | 7.87 | 0.52 |
| MACD | -2.78 | -0.13 |
| Stochastic Oscillator | 5.71 | 17.27 |
Cable One Inc is a telecommunications company that generates revenue from providing broadband, voice, and video services to both residential and business customers. The company derives majority of its revenue from data and video services, which are subscription-based and billed monthly. The company also offers Sparklight TV, an Internet Protocol Television (IPTV) service that enables customers using the Sparklight TV app to stream video channels from the cloud. Additionally, the company earns advertising revenue by selling airtime on its video channels, and it provides voice services over Internet protocols.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.